Named Bioactive Compounds · Compound
Genistein
Strong Evidencecompound
Hermetica Superfood Encyclopedia
Genistein is a soy-derived isoflavonoid that acts as a selective estrogen receptor modulator (SERM), binding to estrogen receptors with tissue-selective effects. This phytoestrogen modulates estrogen metabolism, inhibits inflammatory pathways, and may influence metabolic processes through receptor-mediated mechanisms.
Genistein is a phytoestrogenic isoflavone (4′,5,7-trihydroxyisoflavone) primarily sourced from soybeans (Glycine max L.), accounting for ~60% of dietary soy isoflavones, though it was first isolated in 1899 from Genista tinctoria (dyer's broom). It naturally occurs mostly as the glycoside genistin, which is converted to the active aglycone form through fermentation, acid hydrolysis, or gut microbial metabolism.
The research dossier notably lacks specific clinical trial data, RCTs, or meta-analyses for genistein, with no PubMed PMIDs provided for human studies. While general suggestions exist for potential benefits in obesity, inflammatory bowel disease, and neurodegeneration, no trial designs, sample sizes, or clinical outcomes are substantiated in the available sources.
No clinically studied dosage ranges or standardized forms are specified in the available research. Dietary soy products contain 5.6-276 mg genistein/100g (average 81 mg/100g), but these represent food levels rather than clinical doses. Consult a healthcare provider before starting any new supplement.
Genistein (4',5,7-trihydroxyisoflavone; C₁₅H₁₀O₅; MW 270.24 g/mol) is a naturally occurring isoflavone aglycone and phytoestrogen. It is not a macronutrient source itself but rather a bioactive compound found in soy-based foods and certain legumes. Key details: • Dietary sources and approximate concentrations: Soybeans (raw) contain ~5.6–81 mg genistein per 100 g (varies by cultivar); tofu ~13–25 mg/100 g; tempeh ~19–53 mg/100 g; soy milk ~1–13 mg/100 mL; edamame ~6–14 mg/100 g; miso ~7–20 mg/100 g. Minor amounts found in chickpeas (~0.06 mg/100 g), fava beans, and red clover. • Chemical forms: Occurs naturally as the glycoside genistin (genistein-7-O-β-D-glucoside) and as the aglycone genistein; also found as 6'-O-malonylgenistin and 6'-O-acetylgenistin in unprocessed soy. Fermented soy products (miso, tempeh, natto) contain higher proportions of the free aglycone form. • Bioavailability: Oral bioavailability is moderate but highly variable (~10–30% estimated absorption). The glycoside genistin is hydrolyzed by intestinal β-glucosidases and gut microbiota to release the active aglycone genistein. Aglycone form is absorbed more rapidly (Tmax ~1–2 hours) vs. glycoside form (Tmax ~4–8 hours). Undergoes extensive first-pass hepatic metabolism via UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs), forming genistein-7-O-glucuronide and genistein-4'-O-sulfate as major circulating metabolites. Enterohepatic recirculation extends plasma half-life (~7–8 hours). Gut microbiota-dependent metabolites include dihydrogenistein and 6'-hydroxy-O-desmethylangolensin (6'-OH-DMA); equol is NOT a metabolite of genistein (equol derives from daidzein). Plasma concentrations after typical soy-rich diets (~30–50 mg/day isoflavones) reach ~0.1–1.5 µM. Supplemental doses (40–80 mg/day genistein) can yield plasma levels of ~1–5 µM. • Bioactive properties: Binds estrogen receptors with preferential affinity for ERβ (IC₅₀ ~8.4 nM) over ERα (IC₅₀ ~145 nM); protein tyrosine kinase inhibitor (IC₅₀ ~20–100 µM in vitro); topoisomerase II inhibitor; antioxidant activity (scavenges ROS via phenolic hydroxyl groups); inhibits NF-κB signaling at concentrations ≥10 µM in vitro. • No significant vitamin or mineral content as a pure compound. When consumed via whole soy foods, it is co-ingested with soy protein (~36 g/100 g soybeans), dietary fiber (~9 g/100 g), iron (~15.7 mg/100 g soybeans), calcium (~277 mg/100 g soybeans), magnesium (~280 mg/100 g), potassium (~1797 mg/100 g), folate (~375 µg/100 g), vitamin K₁ (~47 µg/100 g), and other isoflavones including daidzein (~20–60 mg/100 g soybeans) and glycitein (~5–10 mg/100 g). • Solubility and formulation notes: Poorly water-soluble (<1 mg/mL at neutral pH); lipophilic (LogP ~2.84). Bioavailability can be enhanced via lipid-based formulations, micronization, nanoemulsions, or complexation with cyclodextrins. Food matrix effects are significant—soy foods with fat content may enhance absorption.
Genistein binds selectively to estrogen receptor beta (ERβ) with 30-fold higher affinity than estrogen receptor alpha (ERα), modulating gene expression in a tissue-specific manner. It inhibits nuclear factor-kappa B (NF-κB) signaling pathways, reducing pro-inflammatory cytokine production including TNF-α and IL-6. Genistein also inhibits protein tyrosine kinases and activates AMP-activated protein kinase (AMPK), influencing cellular metabolism and energy homeostasis.
Limited human studies have examined genistein's effects, with most research conducted in cell culture and animal models. A 12-week randomized controlled trial in 84 postmenopausal women found 54mg daily genistein improved bone mineral density markers but showed minimal effects on menopausal symptoms. Preliminary studies suggest potential benefits for inflammatory bowel disease, but no large-scale clinical trials have been completed. Most evidence supporting anti-inflammatory and metabolic effects comes from mechanistic studies rather than human clinical data.
Genistein is generally well-tolerated at typical dietary doses (1-5mg daily from soy foods), but supplement doses (25-54mg daily) may cause mild gastrointestinal upset. Due to its estrogenic activity, genistein may interact with hormone replacement therapy and estrogen-sensitive medications like tamoxifen. Women with estrogen-receptor positive breast cancer should consult healthcare providers before supplementation. Pregnancy and breastfeeding safety data is insufficient, and high doses may affect infant development due to hormonal activity.
